Company Filing History:
Years Active: 1998-1999
Title: Inventor Spotlight: Stephen McAndrew
Introduction
Stephen McAndrew is a prominent inventor based in Newtown, Pennsylvania, with a notable contribution to the field of medical research and biotechnology. With two patents to his name, he has focused on developing novel antibodies aimed at combating human carcinomas. His work has significant implications for cancer treatment and therapeutic applications.
Latest Patents
Stephen McAndrew's latest patents include ground-breaking inventions in the field of oncology. One patent describes "Antibodies reactive with human carcinomas," which details novel antibodies, antibody fragments, and immunotoxins that specifically target human carcinoma cells. Among these, the murine monoclonal antibody BR96, and the human/murine chimeric antibody ChiBR96 stand out for their high degree of selectivity for carcinoma cells and ability to mediate cytotoxic effects essential for therapy. The patent also outlines several conjugates and fragments, including ChiBR96-PE and ChiBR96 Fab'-LysPE40, emphasizing their therapeutic potential due to their internalization properties within carcinoma cells.
Another significant patent is focused on "Monoclonal antibody BR110 and uses thereof." This invention centers on internalizing ligands that recognize and bind the BR110 antigen, enabling sophisticated detection methods. The ability of these ligands to form complexes with the antigen enhances diagnostic and therapeutic applications.
Career Highlights
Stephen McAndrew's professional journey is closely tied to Bristol Myers Squibb Company, a leading player in the biopharmaceutical industry. His dedication to research and innovation has made him a valuable contributor to advancing medical science and patient care. His work exemplifies a commitment to harnessing the potential of antibody therapies in fighting cancer.
Collaborations
Throughout his career, McAndrew has collaborated with esteemed colleagues, including Ingegerd E Hellstrom and Karl E Hellstrom. These partnerships have fostered an environment of collective innovation, leading to advancements in therapeutic solutions for cancer treatment.
Conclusion
In summary, Stephen McAndrew is a notable figure in the realm of biomedicine, particularly in the development of antibodies aimed at treating carcinomas. His contributions hold promise for improving cancer therapies and enhancing patient outcomes. As his work continues to evolve, it can be anticipated that McAndrew will remain at the forefront of innovation in the fight against cancer.